Latest Healthcare News

Page 11 of 197
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
Genetic Signatures and Microba Life Sciences have agreed in principle to revise their proposed merger, reducing Microba shareholders’ post-deal ownership from about 67% to 60%. The change improves the position of existing GSS shareholders, but the transaction remains non-binding and subject to multiple approvals.
Victor Sage
Victor Sage
21 Oct 2026
Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.
Ada Torres
Ada Torres
21 Oct 2026
Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.
Ada Torres
Ada Torres
21 Oct 2026
Sigma Healthcare has entered FY27 with double-digit Chemist Warehouse sales growth, stronger earnings and a merger integration program targeting $100 million in annual synergies by FY29. The next test is whether store expansion and technology consolidation can convert momentum into durable cash returns.
Ada Torres
Ada Torres
21 Oct 2026
Pro Medicus has secured a seven-year, A$43 million contract with New Jersey healthcare provider Virtua Health, expanding its cloud-based Visage 7 platform across five hospitals. The transaction-based agreement includes cardiology imaging and offers potential upside beyond the disclosed contract value, although the timing of revenue remains unspecified.
Victor Sage
Victor Sage
21 Oct 2026
Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.
Ada Torres
Ada Torres
20 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Ramsay Health Care’s proposed separation of its 52.79% Ramsay Santé stake has reached a key regulatory milestone, with ASIC registering the Demerger Booklet. Shareholders will vote on the transaction on 24 November, but approval remains only one step in a process that could create two separately traded healthcare exposures.
Ada Torres
Ada Torres
19 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.
Ada Torres
Ada Torres
19 Oct 2026
Pro Medicus has signed a seven-year, A$24 million contract with Billings Clinic - Logan Health for a cloud-based deployment of its Visage 7 imaging platform. The transaction-based structure offers potential additional upside, although the announcement does not quantify future volumes or revenue timing.
Victor Sage
Victor Sage
19 Oct 2026

Browse the archive

Full archive